BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

526139

TRABI

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

TRANSGENE BIOTEK LTD. Share Price Update

As of the latest trading session, TRANSGENE BIOTEK LTD. share price is currently at ₹ 3.74, which is down by ₹ -0.25 from its previous closing. Today, the stock has fluctuated between ₹ 3.60 and ₹ 4.24. Over the past year, TRANSGENE BIOTEK LTD. has achieved a return of -54.03 %. In the last month alone, the return has been -13.26 %. Read More...

Investment Returns

Over 1 Month -13.26% Over 3 Months -4.08% Over 6 Months -5.67% Over 1 Year -54.03%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

TRANSGENE BIOTEK LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    28.30

  • P/E Ratio (TTM)

    -23.47

  • Beta

    0.26

  • Book Value / share

    -0.99

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    -0.43

info icon alternate text

TRANSGENE BIOTEK LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 0.05
Operating Expense 0.49
Net Profit -0.43
Net Profit Margin (%) -860.00
Earnings Per Share (EPS) -0.06
EBITDA -0.13
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.08
Operating Expense 0.83
Net Profit -0.71
Net Profit Margin (%) -887.50
Earnings Per Share (EPS) -0.09
EBITDA -0.50
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.08
Operating Expense 0.21
Net Profit -0.09
Net Profit Margin (%) -112.50
Earnings Per Share (EPS) -0.01
EBITDA -0.04
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 0.06
Operating Expense 0.18
Net Profit -0.07
Net Profit Margin (%) -116.66
Earnings Per Share (EPS) -0.01
EBITDA -0.03
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.05
Operating Expense 0.50
Net Profit 0.20
Net Profit Margin (%) 400.00
Earnings Per Share (EPS) 0.03
EBITDA 0.24
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.26
Operating Expense 1.72
Net Profit -0.68
Net Profit Margin (%) -261.53
Earnings Per Share (EPS) -0.09
EBITDA -0.35
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 0.23
Operating Expense 1.06
Net Profit -0.66
Net Profit Margin (%) -286.95
Earnings Per Share (EPS) -0.09
EBITDA -0.44
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.06
Operating Expense 6.23
Net Profit -6.01
Net Profit Margin (%) -10016.66
Earnings Per Share (EPS) -0.79
EBITDA -0.87
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.09
Operating Expense 10.70
Net Profit -10.40
Net Profit Margin (%) -11555.55
Earnings Per Share (EPS) -1.37
EBITDA -0.25
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 0.17
Operating Expense 10.87
Net Profit -10.43
Net Profit Margin (%) -6135.29
Earnings Per Share (EPS) -1.38
EBITDA -0.25
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.41
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.23
EBITDA Margin -182.61
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.50
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.87
EBITDA Margin -733.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share 2.29
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.59
EBITDA Margin -277.78
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2.94
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.39
EBITDA Margin -152.94
Particulars MAR 2020 (Values in Cr)
Book Value / Share 4.31
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.26
EBITDA Margin 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share -0.91
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -182.61
Particulars MAR 2023 (Values in Cr)
Book Value / Share -0.82
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -733.33
Particulars MAR 2022 (Values in Cr)
Book Value / Share -0.03
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 5.23
EBITDA Margin -277.78
Particulars MAR 2021 (Values in Cr)
Book Value / Share 0.62
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.10
EBITDA Margin -152.94
Particulars MAR 2020 (Values in Cr)
Book Value / Share 1.99
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.47
EBITDA Margin 0.00
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 142.33
Total Liabilities 142.33
Total Equity 10.71
Share Outstanding 75770000
Price to Book Ratio -8.95
Return on Assets (%) -0.46
Return on Capital (%) -2.65
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 142.35
Total Liabilities 142.35
Total Equity 11.36
Share Outstanding 75770000
Price to Book Ratio -3.04
Return on Assets (%) -4.22
Return on Capital (%) -24.54
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 147.10
Total Liabilities 147.10
Total Equity 17.37
Share Outstanding 75770001
Price to Book Ratio -120.33
Return on Assets (%) -7.07
Return on Capital (%) -35.4
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 156.88
Total Liabilities 156.88
Total Equity 22.23
Share Outstanding 75770001
Price to Book Ratio 7.39
Return on Assets (%) -6.65
Return on Capital (%) -31.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.03
Total Assets 166.75
Total Liabilities 166.75
Total Equity 32.67
Share Outstanding 75770000
Price to Book Ratio 1.51
Return on Assets (%) -6.57
Return on Capital (%) -25.49
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 32.44
Total Liabilities 32.44
Total Equity -6.87
Share Outstanding 75770000
Price to Book Ratio -8.95
Return on Assets (%) -2.02
Return on Capital (%) -9.19
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.00
Total Assets 32.47
Total Liabilities 32.47
Total Equity -6.20
Share Outstanding 75770000
Price to Book Ratio -3.04
Return on Assets (%) -18.49
Return on Capital (%) -86.87
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 37.21
Total Liabilities 37.21
Total Equity -0.19
Share Outstanding 75770000
Price to Book Ratio -120.33
Return on Assets (%) -27.94
Return on Capital (%) -88.01
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 46.99
Total Liabilities 46.99
Total Equity 4.66
Share Outstanding 75770000
Price to Book Ratio 7.39
Return on Assets (%) -22.20
Return on Capital (%) -65.23
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.03
Total Assets 56.86
Total Liabilities 56.86
Total Equity 15.09
Share Outstanding 75770000
Price to Book Ratio 1.51
Return on Assets (%) -19.27
Return on Capital (%) -43.12
Particulars MAR 2024 (Values in Cr)
Net Income -0.65
Cash from Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash 0.00
Free Cash Flow 0.00
Particulars MAR 2023 (Values in Cr)
Net Income -6.00
Cash from Operations 0.00
Cash from Investing -0.01
Cash from Financing 0.00
Net change in Cash -0.01
Free Cash Flow 0.00
Particulars MAR 2022 (Values in Cr)
Net Income -10.40
Cash from Operations 0.09
Cash from Investing -0.09
Cash from Financing 0.00
Net change in Cash 0.00
Free Cash Flow 0.09
Particulars MAR 2021 (Values in Cr)
Net Income -10.43
Cash from Operations 0.01
Cash from Investing -0.02
Cash from Financing 0.00
Net change in Cash -0.01
Free Cash Flow 0.03
Particulars MAR 2020 (Values in Cr)
Net Income -10.96
Cash from Operations 0.13
Cash from Investing 0.00
Cash from Financing -0.20
Net change in Cash -0.06
Free Cash Flow 0.13
Particulars MAR 2024 (Values in Cr)
Net Income -0.65
Cash from Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00
Net change in Cash 0.00
Free Cash Flow 0.00
Particulars MAR 2023 (Values in Cr)
Net Income -6.00
Cash from Operations 0.00
Cash from Investing -0.01
Cash from Financing 0.00
Net change in Cash -0.01
Free Cash Flow 0.00
Particulars MAR 2022 (Values in Cr)
Net Income -10.40
Cash from Operations 0.09
Cash from Investing -0.09
Cash from Financing 0.00
Net change in Cash 0.00
Free Cash Flow 0.09
Particulars MAR 2021 (Values in Cr)
Net Income -10.43
Cash from Operations 0.01
Cash from Investing -0.03
Cash from Financing 0.00
Net change in Cash -0.02
Free Cash Flow 0.03
Particulars MAR 2020 (Values in Cr)
Net Income -10.96
Cash from Operations 0.13
Cash from Investing 0.00
Cash from Financing -0.20
Net change in Cash -0.06
Free Cash Flow 0.13
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7676.95 70.15 13.45 110382.76 6002.15 / 7981.20
FORTIS MALAR HOSPITALS LIMITED 67.36 27.38 4.18 126.24 51.01 / 98.70
SHREE PACETRONIX LTD. 167.30 57.69 4.36 60.22 61.11 / 187.00
VIMTA LABS LIMITED 656.00 48.02 8.51 2919.57 254.43 / 728.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7676.95 81.68 12.63 110382.76 6002.15 / 7981.20
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 37.98 0.00 -15.01 28.37 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 6299.05 31.26 6.34 6891.16 4777.15 / 6525.00

TRANSGENE BIOTEK LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
3.74 -6.26 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 4.00
  • 26 Days 4.40
  • 10 Days 4.20
  • 50 Days 4.50
  • 12 Days 4.20
  • 100 Days 4.50
  • 20 Days 4.30
  • 200 Days 5.00
3.90 PIVOT

First Support

3.66

First Resistance

4.24

Second Support

3.32

Second Resistance

4.48

Third Support

3.08

Third Resistance

4.82

RSI

37.35

ADX

19.30

MACD

-0.19

Williams % R

-72.55

Commodity Channel Index (CCI)

-153.51

Date

2025-09-01

Week

27345.00

Same Day

15092.00

Month

25825.00

1 Year

0.26

3 Year

0.22

Over 1 Month

-13.26%

down

Over 1 Year

-54.03%

down

Over 3 Months

-4.08%

down

Over 3 Years

7.18%

down

Over 6 Months

-5.67%

down

Over 5 Years

-4.37%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

TRANSGENE BIOTEK LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

TRANSGENE BIOTEK LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

TRANSGENE BIOTEK LTD. Share Price

Founded in March, 1990 by Dr. Koteswara Rao, Transgene Biotek Ltd was one of the first Biotechnology companies in India. Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc. The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune.

Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.

Transgene Biotek's products are exported to Africa, Russia, China, Malaysia and the Phillipines. The company chalked out a new project for setting up a manufacturing facility costing Rs. 30 crore at the Anrich Industrial Area, Bollaram. TBL is working of four new plants comprising of Oral deliver of proteins and peptides; DNA vaccines; fusion proteins and bio therapeutics. The new project is funded through preferential offer to Batterymarch Financial Management USA and Other Financial Institutions (FIs).

The Company absorbed the transfer of technology from RBB Inc, USA for the manufacture and marketing of Erythropoietin during year 2003.

The Scheme of Arrangement for Amalgamation of M/S Saket Biotechnologies Private Limited (SBPL) with the Company was implemented and made effective on 7th February, 2005. In terms of the said Scheme of Amalgamation, 60,60,000 Equity Shares were allotted to the Sharesholders of M/S Saket Biotechnologies Private limited on 27 April 2005.

In 2012-13, the Company started the commercial production of Omega-3 DHA (Docosahexaenoic Acid) . It formulated the molecule belonging to a very large global pharma company for undergoing studies at its own chosen facilities in USA during year 2020-21.

Transgene has been developing novel oral and nasal formulations for the delivery of various protein and peptide-based biologicals through oral and intra-nasal routes. Transgene is focused on developing novel therapies in the areas of Oncology, Auto-Immune diseases and new drug delivery technologies, that have the potential to substantially improve the quality of life of patients in areas of unmet medical need.

Parent organization Indian Private
NSE symbol [-]
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Transgene Biotek Ltd?

Answer Field

Transgene Biotek Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 3.74 as on Sep 02 2025 03:29 PM.

What is the Market Cap of Transgene Biotek Ltd Share?

Answer Field

The market cap of Transgene Biotek Ltd for NSE ₹ 0.00 & for BSE ₹ 28.30 as on Sep 02 2025 03:29 PM.

What is the 52 Week High and Low of Transgene Biotek Ltd?

Answer Field

The 52 Week High and Low of Transgene Biotek Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 8.88 and ₹ 3.22.

What is 1 year return for Transgene Biotek Ltd?

Answer Field

The 1 year returns on the stock has been -54.03%.

What is the P/E Ratio of Transgene Biotek Ltd Share?

Answer Field

As on Sep 02 2025 03:29 PM the price-to-earnings (PE) ratio for Transgene Biotek Ltd share is -23.47.

What is the PB ratio of Transgene Biotek Ltd Share?

Answer Field

As on Sep 02 2025 03:29 PM, the price-to-book (PB) ratio for Transgene Biotek Ltd share is -0.99.

How to Buy Transgene Biotek Ltd Share?

Answer Field

You can trade in Transgene Biotek Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Transgene Biotek Ltd Share on Bajaj Broking App?

Answer Field

To buy Transgene Biotek Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Transgene Biotek Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91